共 235 条
[1]
DeMatteo RP(2000)Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann. Surg. 231 51-58
[2]
Lewis JJ(1998)Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577-580
[3]
Leung D(2004)Biology of gastrointestinal stromal tumors J. Clin. Oncol. 22 3813-3825
[4]
Mudan SS(2010)NCCN task force report: update on the management of patients with gastrointestinal stromal tumors J. Natl Compr. Canc. Netw. 8 1-41
[5]
Woodruff JM(2004)Use of c-KIT/ PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 40 689-695
[6]
Brennan MF(2003)Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J. Clin. Oncol. 21 4342-4349
[7]
Hirota S(2009)Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors Clin. Cancer Res. 15 7510-7518
[8]
Isozaki K(2006)Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329-1338
[9]
Moriyama Y(2013)Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 295-302
[10]
Hashimoto K(2013)Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations PLoS ONE 8 E65762-251